Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Ajai ChariMonique C MinnemaJesus G BerdejaAlbert OriolNiels W C J van de DonkPaula Rodríguez-OteroElham AskariMaría-Victoria MateosLuciano José Megale CostaJo CaersRaluca VeronaSuzette GirgisShiyi YangRachel B GoldsmithXiang YaoKodandaram PillarisettiBrandi W HilderJeffery RussellJenna D GoldbergAmrita KrishnanPublished in: The New England journal of medicine (2022)
Cytokine release syndrome, skin-related events, and dysgeusia were common with talquetamab treatment but were primarily low-grade. Talquetamab induced a substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma. (Funded by Janssen Research and Development; MonumenTAL-1 ClinicalTrials.gov number, NCT03399799.).